Using genomic profiling for understanding and improving response to smoking cessation treatment.

ABSTRACT:

Purpose of review

This review focuses on the implementation of genomic discoveries associated with smoking behaviors and smoking-related illnesses to improve prevention efforts and smoking cessation.

Recent findings

Large-scale studies have discovered genomic variation that contributes to smoking heaviness and smoking cessation. Variation in the α5 nicotinic acetylcholine receptor subunit (CHRNA5) and the primary nicotine metabolizing gene (CYP2A6) strongly contribute to smoking behaviors, lung cancer, and chronic obstructive pulmonary disease. The analytic and clinical validity of these genes is clearly established, and evidence of clinical utility for risk stratification is growing. Equity will be a critical issue facing the translation of genomic findings in

SUBMITTER: Bierut LJ 

PROVIDER: S-EPMC9586182 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature